Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 3, 2025Journal of Clinical OncologyOpen Access

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SJSundar JagannathTMThomas G. MartinYLYi Lin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jagannath et al. (2025) studied this question.

synapsesocial.com/papers/69279c42bf2ec761a8f9877dhttps://doi.org/10.1200/jco-25-00760
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations